ES2574557T3 - Miméticos dopaminérgicos - Google Patents

Miméticos dopaminérgicos Download PDF

Info

Publication number
ES2574557T3
ES2574557T3 ES05799591.2T ES05799591T ES2574557T3 ES 2574557 T3 ES2574557 T3 ES 2574557T3 ES 05799591 T ES05799591 T ES 05799591T ES 2574557 T3 ES2574557 T3 ES 2574557T3
Authority
ES
Spain
Prior art keywords
hydroxybutyrate
ketosis
symptoms
symptomatic relief
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05799591.2T
Other languages
English (en)
Inventor
Keith Frank Martin
David John Heal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BTG International Ltd filed Critical BTG International Ltd
Application granted granted Critical
Publication of ES2574557T3 publication Critical patent/ES2574557T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Abstract

Un material cetógeno seleccionado de entre (R)-3-hidroxibutirato, (R)-3-hidroxibutirato oligómero y ésteres de (R)-3-hidroxibutirato con glicerol o (R)-butano-1,3-diol, para su uso en el suministro de un alivio sintomático agudo para los síntomas de la enfermedad de Parkinson resultantes de un déficit de dopamina en el encéfalo por administración a una dosis de 50 a 1.000mg/kg de peso corporal al día para producir una cetosis de tal manera que la concentración total de acetoacetato y (R)-3-hidroxibutirato en la sangre se eleva a entre 0,5 y 8mM; caracterizado porque la administración proporciona una dosis terapéuticamente efectiva del material cetógeno para el alivio sintomático agudo de uno o más de los síntomas del síndrome motor de bradicinesia (movimientos lentos), discinesia (movimientos anómalos), acinesia (rigidez), temblor en reposo, inestabilidad postural y déficits del habla; donde estos síntomas se reducen durante este periodo de cetosis, con la instauración de alivio sintomático en un máximo de dos horas desde el inicio de la cetosis.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
ES05799591.2T 2004-09-21 2005-09-21 Miméticos dopaminérgicos Active ES2574557T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61130204P 2004-09-21 2004-09-21
US611302P 2004-09-21
PCT/US2005/033860 WO2006034361A2 (en) 2004-09-21 2005-09-21 Dopaminergic mimetics

Publications (1)

Publication Number Publication Date
ES2574557T3 true ES2574557T3 (es) 2016-06-20

Family

ID=36090656

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05799591.2T Active ES2574557T3 (es) 2004-09-21 2005-09-21 Miméticos dopaminérgicos

Country Status (5)

Country Link
US (7) US20070281892A1 (es)
EP (1) EP1796658B1 (es)
DK (1) DK1796658T3 (es)
ES (1) ES2574557T3 (es)
WO (1) WO2006034361A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2146711A4 (en) 2007-04-12 2011-10-26 Univ Minnesota PROTECTIVE COMPOSITIONS AGAINST ISCHEMIA / REPERFUSION AND METHODS OF USE
US11229364B2 (en) * 2013-06-14 2022-01-25 Medtronic, Inc. Patient motion analysis for behavior identification based on video frames with user selecting the head and torso from a frame
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
CN113329990A (zh) * 2019-01-17 2021-08-31 Ioi油脂化学品有限责任公司 羟基羧酸甘油酯的生产方法
TWI804037B (zh) * 2021-11-02 2023-06-01 長庚醫療財團法人高雄長庚紀念醫院 生酮飲食之評估系統及其運作方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637726A (es) * 1962-09-26
US3665075A (en) * 1970-08-07 1972-05-23 American Cyanamid Co Thozalinone as an antiparkinson agent
US4363815A (en) * 1975-07-23 1982-12-14 Yu Ruey J Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions
DE2733202A1 (de) * 1976-08-04 1978-02-09 Agroferm Ag Verfahren zur herstellung der d(-)-3-hydroxybuttersaeure
US4067999A (en) * 1976-12-15 1978-01-10 Food Technology Products Control of hemorrhagic enteritis in turkeys
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
US4351835A (en) * 1981-04-01 1982-09-28 Montefiore Hospital Method for preventing body fat deposition in mammals
FR2521857B1 (fr) * 1982-02-23 1985-10-31 Solvay Compositions pharmaceutiques contenant de l'acide 3-hydroxybutanoique ou un sel derive de cet acide et sels derives de l'acide 3-hydroxybutanoique et d'une base organique azotee
US4701443A (en) * 1983-03-22 1987-10-20 Baxter Travenol Laboratories, Inc. Nutrient polyesters
US5100677A (en) * 1985-12-18 1992-03-31 Veech Richard L Fluid therapy with various organic anions
EP0215138B1 (fr) * 1985-09-06 1991-01-16 Societe Des Produits Nestle S.A. Préservation des tissus vivants
GB8525666D0 (en) * 1985-10-17 1985-11-20 Ici Plc Chemical process
US5719119A (en) * 1985-12-18 1998-02-17 British Technology Group, Ltd. Parenteral nutrition therapy with amino acids
EP0258273A1 (en) * 1985-12-20 1988-03-09 VEECH, Richard L. Preparation of electrolyte solutions and containers
US4997976A (en) * 1988-11-15 1991-03-05 Henri Brunengraber Use of 1,3-butanediol acetoacetate in parenteral oral nutrition
US5126373A (en) * 1987-11-19 1992-06-30 Henri Brunengraber Composition for parenteral and oral nutrition
US5292774A (en) * 1988-07-26 1994-03-08 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Substitution fluid preparation comprising 3-hydroxy-butyric acid (β-hydroxybutric acid) and its salts
US5116868A (en) * 1989-05-03 1992-05-26 The Johns Hopkins University Effective ophthalmic irrigation solution
EP0522422A3 (en) * 1991-07-01 1993-03-17 Mitsubishi Kasei Corporation Process for producing a biodegradable polymer
US5654266A (en) * 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
US5348979A (en) * 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
WO1995009144A1 (en) * 1993-09-30 1995-04-06 Eastman Chemical Company Nutritive water soluble glycerol esters of hydroxy butyric acid
US5912269A (en) * 1996-04-30 1999-06-15 Vertex Pharmaceuticals, Inc. Butyrate prodrugs derived from lactic acid
JP4598203B2 (ja) * 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
DE69903792T2 (de) * 1998-01-07 2003-08-14 Metabolix Inc Tierfutterzusammensetzungen
US6417210B1 (en) * 1998-01-09 2002-07-09 Mor-Research Applications Ltd. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
ATE239464T1 (de) * 1998-01-21 2003-05-15 Fideline Pheromone enthaltende zusammensetzung zur minderung von stress, angst und streitsucht in schweinen
WO2002051395A1 (en) * 1998-05-28 2002-07-04 Codon Pharmaceuticals, Inc. Treatment of neurodegenerative diseases
ATE283056T1 (de) * 1998-07-22 2004-12-15 Metabolix Inc Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere
KR100805490B1 (ko) * 1998-09-15 2008-02-20 비티지 인터내셔널 리미티드 치료 조성물 （ⅱ）
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
AU2001257451A1 (en) * 2000-05-01 2001-11-12 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US20020132846A1 (en) * 2001-02-26 2002-09-19 Caleb Stone Use of gamma substituted gamma-butyrolactones to increase levels of their corresponding substituted gamma-hydroxybutyrate derivatives in humans
US6670378B2 (en) * 2001-05-08 2003-12-30 Pharmacia & Upjohn Company Method of treating Parkinson's disease
CA2517929A1 (en) * 2003-03-06 2004-09-16 Accera Inc. Novel-chemical entities and methods for their use in treatment of metabolic disorders
WO2006012490A2 (en) * 2004-07-23 2006-02-02 Ketocytonyx Inc. Ketogenic saccharides
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition

Also Published As

Publication number Publication date
EP1796658B1 (en) 2016-03-30
US20070281892A1 (en) 2007-12-06
EP1796658A4 (en) 2007-12-12
EP1796658A2 (en) 2007-06-20
US20180338938A1 (en) 2018-11-29
DK1796658T3 (en) 2016-06-27
US20150141511A1 (en) 2015-05-21
US20170035712A1 (en) 2017-02-09
WO2006034361A2 (en) 2006-03-30
US20110065656A1 (en) 2011-03-17
US20210077440A1 (en) 2021-03-18
US20230165817A1 (en) 2023-06-01
WO2006034361A3 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
ES2574557T3 (es) Miméticos dopaminérgicos
CL2021003222A1 (es) (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.
ES2510565T3 (es) Envase de ajuste de dosis para neramexano y su uso en el tratamiento de un trastorno del oído interno
AR109170A2 (es) Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente
ES2480291T3 (es) Dilatador nasal con capa de almohadilla y coeficiente de elasticidad variable
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
ES2526648T3 (es) Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno
ECSP055793A (es) Forma de administración de ibuprofeno sódico
MA30266B1 (fr) Utilisation de deferiprone et methodes de traitement prophylactique et/ou therapeutique de la maladie de friedreich resultant d'un dysfonctionnement du traitement intracellulaire du fer
HUP0204459A2 (en) Method for the improvement of islet signaling in diabetes mellitus and for its prevention
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
ES2531516T3 (es) Uso de escina
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
ES2422286T3 (es) Uso de apamina para tratar la enfermedad de Parkinson
ES2563068T3 (es) Tratamiento de esclerosis múltiple (MS) con Campath-1H
ES2421709T3 (es) Uso de veneno de abeja para tratar la enfermedad de Parkinson
ES2497766T3 (es) Composiciones y procedimientos de sensibilizar a oxacilina Staphylococcus aureus resistente a meticilina
Erejuwa et al. Effects of Malaysian tualang honey supplementation on glycemia, free radical scavenging enzymes and markers of oxidative stress in kidneys of normal and streptozotocin-induced diabetic rats
CO5690605A2 (es) Cci-779 para tratar linfoma de celulas del manto
AR029666A1 (es) Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina
RU2016103098A (ru) Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii
ES2526359T3 (es) Formulación galénica oral que comprende ketorolaco y vitaminas del complejo B, en la que la vitamina B6 se encuentra en una capa externa separada del resto de principios activos
RU2008124830A (ru) Производное рапамицина или ингибитор impdh для лечения поликистозного заболевания почек
CL2004000984A1 (es) Forma de dosificacion oral de una sal de magnesio de (s)-pantopazol, para la profilaxis o tratamiento de una condicion asociada a inhibir la bomba protonica.
ES2533046T3 (es) Oleíl-fosfocolina